MET exon 14 skipping lung cancer: testing and targeted treatment

Understand the wording MET exon 14 skipping

This alteration affects how the MET gene's message is processed, allowing signaling that can help cancer grow. A laboratory may identify different underlying changes that lead to the same exon-skipping effect. The report should clearly state the clinically relevant interpretation.

Ask whether the finding is established by the assay used and whether additional testing would resolve any uncertainty. A general note of MET abnormality is not enough to assume that the exon 14 treatment pathway applies. Keep the original result available for another specialist.

Sources and references: [1] [2]

Separate skipping, amplification and expression

MET amplification describes extra gene copies. MET protein overexpression refers to a staining result. These can arise in different clinical situations, including resistance after an EGFR-targeted medicine, and may call for a different therapy or research pathway.

Ask which category your report demonstrates. If MET amplification appeared after osimertinib, the team should assess it as a possible resistance mechanism alongside the original EGFR mutation. A treatment article about newly diagnosed MET exon 14 disease answers a different question.

Sources and references: [2] [3]

Targeted options depend on stage and local indication

Capmatinib and tepotinib are established MET-directed options in defined advanced NSCLC settings. The FDA granted traditional approval to tepotinib in 2024 for adults with metastatic NSCLC harboring MET exon 14 skipping alterations.

Ask the oncologist which locally available medicine fits your diagnosis and whether previous treatment changes the choice. If your cancer is at an earlier, potentially curable stage, surgery or radiation planning still needs its own assessment. A molecular target should be incorporated into the stage-specific plan.

Sources and references: [1] [4]

Savolitinib's China indication includes untreated patients

In January 2025, China expanded savolitinib's indication to adults with locally advanced or metastatic NSCLC with MET exon 14 skipping, covering both previously treated and untreated patients. This creates a relevant option to discuss when considering care in China.

The single-drug MET exon 14 indication should be distinguished from savolitinib with osimertinib for a different EGFR and MET resistance setting. Share the full report so the hospital can assess the correct use and explain the current prescribing and monitoring arrangements.

Sources and references: [5] [3]

Include brain disease in the comparison

Some MET inhibitors have reported activity against brain metastases. The team still needs to assess the number, size, symptoms and location of any lesions. A medicine's brain activity can influence the sequence, while a symptomatic or threatening metastasis may need prompt local treatment.

Ask whether baseline brain MRI is indicated and how follow-up will be arranged. If the brain changes while disease elsewhere remains controlled, a separate local-treatment discussion may be useful. New neurological symptoms should bring the assessment forward.

Sources and references: [1] [6]

Swelling and other side effects deserve an early plan

Peripheral edema can be troublesome during MET-inhibitor treatment. Report swelling, weight changes and how they affect walking or shoes. The team may assess other causes and decide on supportive measures or a dose adjustment.

Liver tests, kidney-related laboratory changes and respiratory symptoms can also need review, depending on the medicine. New cough or shortness of breath should be reported promptly because drug-related lung inflammation is one possible cause. Avoid starting a diuretic or changing the cancer dose without the prescribing team's advice.

Sources and references: [1] [4]

Reassess before choosing another MET treatment

At progression, the team considers whether growth is limited to a few sites or is more widespread. Repeat testing may identify a resistance mechanism, although the result needs to be interpreted with the drug history. Another MET inhibitor may not address the same resistance pattern.

Chemotherapy-based treatment or a clinical trial may be considered according to the situation. Ask what a new test could change and how the next option compares with the treatment you have already received. Include any lasting side effects in that assessment.

Sources and references: [1] [7] [8]

A focused MET review in Shanghai

For a Shanghai inquiry, EastMedGo can help organize your molecular report, recent scans and treatment timeline. The molecular-review resources are relevant when the report uses different MET terms or when resistance has developed.

Tell us whether you are choosing the first treatment or seeking an option after a MET inhibitor. We can help clarify hospital assessment requirements and coordination arrangements. The receiving team can then address the exact biomarker, local drug indication and follow-up needs before travel.

Common questions